Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Liver function as a predictor of mortality in COVID-19: A retrospective study

Fikret Salik*, Osman Uzundere, Mustafa Bıçak, Hakan Akelma, Mesut Akgündüz, Zeki Korhan, Deniz Kandemir, Cem Kivilcim Kaçar

Gazi Yaşargil Training and Research Hospital, Anesthesiology and Reanimation Clinic, Diyarbakır 21010, Turkey

A R T I C L E   I N F O
Article History:
Received 3 April 2021
Accepted 19 April 2021
Available online 6 October 2021

Keywords:
Coronavirus disease 2019
Critically ill patient
Intensive care unit
Liver injury
Liver biochemical parameters abnormalities
Mortality

A B S T R A C T

Introduction and Objectives: In many studies, varying degrees of liver damage have been reported in more than half of the COVID-19 patients. The aim of this study is to determine the effect of liver biochemical parameters abnormality on mortality in critical COVID-19 patients who have been followed in the ICU since the beginning of the pandemic process.

Materials and Methods: In this study 533 critical patients who admitted to the ICU due to COVID-19 were included. The patients were divided into three groups according to their ALT, AST, and total bilirubin levels at their admission to the ICU. Group 1 was formed of patients with normal liver biochemical parameters values; Group 2 was formed of patients with liver biochemical parameters abnormality; Group 3 was formed of patients with liver injury.

Results: 353 (66.2%) of all patients died. Neutrophil, aPTT, CRP, LDH, CK, ALT, AST, bilirubin, procalcitonin and ferritin values in Group 2 and Group 3 were found to be statistically significantly higher than Group 1. It was detected that the days of stay in ICU of the patients in Group 1 was statistically significantly longer than others group. It was found that the patients in Groups 2 and 3 had higher total, 7-day, and 28-day mortality rates than expected.

Conclusions: The study showed that liver dysfunction was associated with higher mortality and shorter ICU occupation time.

© 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

In a number of studies, varying degrees of liver damage have been noted in more than half of the patients who diagnosed COVID-19 [1,2]. It has been shown that the SARS-CoV-2 receptor, called ACE 2, is also present highly in bile duct cells except alveolar epithelial cells [3,4]. Some studies support that SARS-CoV-2 can also infect bile duct cells through this receptor and cause liver biochemical parameters abnormality [5]. In previous studies, it has been noted that 14-78% of COVID-19 patients have an increase in liver biochemical parameters [1,2,6–9]. Additionally, microvesicular steatosis, lobular activity and portal activity were demonstrated in liver biopsy specimens of one patient who died from COVID-19 [10]. This suggests that SARS-CoV-2 may have caused liver damage. Liver dysfunction that develops in these patients can cause to failure of liver and death [11]. For this reason, it is important to investigate liver damage in COVID-19 cases.

Considered the highly contagious and pathogenic nature of SARS-CoV-2 and the high incidence of liver damage, evaluation of liver function in COVID-19 patients is important [5]. Previous studies have reported an association between liver function and duration of hospital stay [5], risk of progression to severe COVID-19 [7–9], and mortality [12].

The aim of this study is to retrospectively determine the effect of liver biochemical parameters abnormalities on mortality in critical patients with COVID-19 who have been followed in the ICU since the beginning of the pandemic process.
2. Materials and methods

2.1. Study design

Critical COVID-19 patients who admitted to the ICU of our hospital between April 2020 and October 2020 and who was confirmed with real-time reverse transcriptase-polymerase chain reaction (RT-PCR) test were included in this retrospective cohort study. The necessary permits have been taken from The Republic of Turkey Ministry of Health Scientific Research Platform (11/20/2020) and Diyarbakir Gazi Yaşargil of Education and Research Hospital (21/11/2020). The trial was registered with clinicaltrials.gov (NCT04669509). This study was carried out in accordance with the Helsinki Declaration criteria.

2.2. Inclusion and exclusion criteria

Critical patients who had COVID-19 and admitted to the ICU on the dates specified, 18 > age, in serious need of oxygen support according to WHO [13] and the temporary guidelines of The Republic of Turkey Ministry of Health Scientific Committee [14], (respiratory rate > 30 / min. and/or severe respiratory distress and/or oxygen saturation at room air < 90% (the patient receiving oxygen PaO2 / FiO2 < 300); bilateral diffuse pneumonia findings detected on chest images; developed or had severe pneumonia, ARDS, sepsis, septic shock and acute renal failure, were included. Patients who 18 < age, pregnant, with a history of liver disease or chronic viral hepatitis infection, whose data are not fully available in the hospital system or the patient file records, with mild-moderate symptoms, no respiratory distress, and no signs of diffuse pneumonia in chest radiography or tomography, and non COVID-19 were excluded.

2.3. Demographic and clinical data

The patients’ age, gender, comorbidity, and complaints were recorded. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, hemogram parameters (white blood cell (WBC), neutrophil, lymphocyte, platelet count), coagulation parameters (prothrombin time (PTZ), Activated Partial Thromboplastin Time (aPTT), and D-dimer), blood biochemistry values (C-reactive protein (CRP), lactate dehydrogenase (LDH), creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, direct bilirubin, and indirect bilirubin; c702-502 autoanalyzer, Roche, Ros-bach, Germany), procalcitonin and ferritin levels were recorded at the time of the ICU admission. In addition, the ICU days, 7-day, 28-day, and total mortality were recorded. Clinical data were collected from the hospital’s computer system. Patient data were rechecked for erroneous data before the last data entry and entered into a computerized database.

2.4. Liver biochemical parameters

All published literature which analyzed liver biochemical parameters in COVID-19 patients was examined through databases and shown in Table 1 [5,6,11,15–37]. Based on previous studies, liver biochemical parameters abnormalities were defined as the elevation of the following liver enzymes in serum: ALT > 40 U / L, AST > 40 U / L, and total bilirubin> 1.20 mg/d L. As in a previous study, we defined ALT and/or AST over three times upper limits of normal (ULN), and/or total bilirubin over two times ULN as liver injury [7].

2.5. COVID-19 severity on mortality

Patients were divided into three groups according to liver biochemical parameters values at their admission to the ICU. Group 1 was formed of patients with normal liver biochemical parameters values; Group 2 was formed of patients with liver biochemical parameters abnormality; Group 3 was formed of patients with liver injury. All three groups were compared in terms of clinical characteristics, APACHE II and SOFA scores, laboratory values, days of ICU stay, 7-day, 28-day, and total mortality.

2.6. Statistical analysis

SPSS 22.0 for Windows program (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Numerical data were expressed as means with standard deviation. Categorical data as frequencies with percentages. Comparison of categorical data between groups was made using the chi-square test and the results were given as n%. Whether the numerical data fit the normality distribution was evaluated using the Kolmogorov–Smirnov test. The Kruskal Wallis test was used in the comparison of the groups, as the numerical data did not conform to the normal distribution. Student-t and Mann–Whitney U tests were used to compare groups in pairs. In all comparisons, p < 0.05 was considered significant.

3. Results

In the study, the data of 567 patients in total were accessed. After exclusion criteria, 34 patients were excluded, and the study was completed with 533 patients. The patients’ mean age was 69.2 ± 14.8 years. 283 (53.1%) patients were male and 250 (46.9%) were female. In total, 401 (75.2%) patients had at least one comorbidity and the most common comorbidities were hypertension (218, 40.9%) and diabetes (151, 28.3%). Between the dates of the study, 353 of all patients died. The mortality rate was found to be 66.2%. The average stay in the ICU was 11.3 ± 10.7 days. The patients’ demographic and clinical data are represented in Table 2.

3.1. Clinical outcomes

When the groups were compared in terms of demographic and clinical characteristics, it was found that the rates of liver biochemical parameters abnormality and liver injury were higher in the male patients than in the female patients (p < 0.001). In addition, those with liver damage were found to have statistically significantly higher SOFA scores (p < 0.001) (Table 2).

When the groups were compared in terms of laboratory values at the time of first admission to the ICU, the neutrophil, aPTT, CRP, LDH, CK, ALT, AST, total bilirubin, direct bilirubin, indirect bilirubin, procalcitonin, and ferritin values were statistically significantly higher in Group 2 and Group 3 than Group 1 (p = 0.047 for neutrophil; p = 0.025 for aPTT; p = 0.033 for CRP; p = 0.001 for other values). Although most laboratory values were found to be higher in Group 3 than Group 2, mean CRP and indirect bilirubin values were higher in Group 2 than Group 3, but this difference was not statistically significant in the dual analysis performed (p = for CRP. 0.36; p = 0.87 for indirect bilirubin) (Table 2).

3.2. Association of liver biochemical parameters abnormality with death and COVID-19

It was found that the length of ICU stay of the patients were statistically significantly longer in Group 1 than in Groups 2 and 3 (p = 0.033). When Group 2 and Group 3 were compared, it was found that the duration of stay in the ICU of the patients were statistically significantly shorter in Group 3 than in Group 2 (p = 0.042) (Table 2).

It was found that the patients in Groups 2 and 3 had higher total, 7-day, and 28-day mortality rates than expected (p-values: 0.004; 0.001; 0.003, respectively) (Table 3).
Liver damage in COVID-19 patients can be attributed to a number of secondary effects of the disease as well as the primary infection. Alternative etiologies such as systemic inflammatory response and cytokine storm associated with COVID-19, drug-induced liver damage, hypoxia, hepatic ischemia, and shock can be counted among these secondary effects [15,38]. Compared to the normal liver biochemical parameters group, we found that patients with liver biochemical parameters abnormality and liver injury had higher levels of neutrophils, CRP, procalcitonin, and ferritin, which may be associated with an immune response after virus infection. This suggests that the inflammatory response also contributes to the occurrence of COVID-19 associated liver damage.

4. Discussion

In this study, liver biochemical parameters abnormality and liver injury were detected in 52% of critical COVID-19 patients during the stay in the ICU. Neutrophil, CRP, LDH, CK, procalcitonin, and ferritin values were found to be higher in patients with liver biochemical parameters abnormality and liver injury compared to patients with normal liver biochemical parameters. In addition, it was determined that patients with liver biochemical parameters abnormality and liver injury had a shorter stay in the ICU than expected, and higher total, 7-day, and 28-day mortality rates compared to patients with normal liver biochemical parameters.
In a systematic review of 107 studies from various countries, Kul-karni et al. reported that 19.2% of COVID-19 survivor patients and 43.3% of COVID-19 non-survivor patients had elevated liver biochemical parameters (elevated was defined as AST or ALT levels above 40 U/L and severe liver injury was defined as any elevation of enzymes over three times ULN and bilirubin over 2 ULN) at the first admission) [39]. In another review, Xu et al. reported that the incidence of liver damage in COVID-19 patients ranged from 14.8% to 53%; and serum ALT and AST levels increased up to 7590 U/L and 1445 U/L, respectively, in a severe COVID-19 patient [40]. Recent studies conducted in the United States reveal abnormal liver biochemical parameters (abnormalities were defined as AST >33 U/L, ALT >34 U/L and TBIL >1.2 mg/dL) association with severity, ICU stay, mechanical ventilation, and death. And they found that abnormal liver biochemical parameters are usually minimally elevated (1–2 × ULN), although more-severe hepatitis (2–5 × or >5 ×) may be observed. [41]. Parohan et al. noted that the incidence of liver damage ranged from 58% to 78% in patients with severe COVID-19, and the higher serum levels of AST (weighted mean difference, 8.84 U/L), ALT (weighted mean difference, 7.35 U/L) and total bilirubin (weighted mean difference, 2.30 mmol/L) were associated with severe outcome from COVID-19 infection [42]. In a retrospective study Zhang et al. reported that the mean level of ALT, AST or total bilirubin in severe COVID-19 patients were higher than that in mild (37.87 ± 32.17 vs 21.22 ± 12.67; 38.87 ± 22.55 vs 24.39 ± 9.79; 14.12 ± 6.37 vs 10.27 ± 4.26) [9]. Similarly, Huang et al. found that the rate of high AST value was higher in ICU patients (62%) than non-ICU patients (25%) (mean values respectively 44.0 U/L vs 34.0 U/L) [6]. In this study, 43.3% of critical COVID-19 patients were found to have liver biochemical parameters abnormality and 8.6% were found to have liver injury during the stay in the ICU. The results of our study are in line with previous studies.

It has been stated in some publications that the rate of male patients is higher in severe COVID-19 compared to female patients [12,21,23,41,43]. In addition, it has been reported that patients with abnormal liver biochemical parameters and liver injury in COVID-19 patients are mostly male patients, but the underlying mechanism is not clear [5,7]. In our study, 53.1% of our total number of patients were male, and in accordance with previous studies, it was deter-

![Table 2](image)

**Table 2**

| Demographic, clinical and laboratory characteristics (Mean±SD). |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age                         | 69.2 ± 14.8     | 69.1 ± 15.6     | 69.7 ± 13.9     | 67.0 ± 15.0     | 0.48            |
| Gender                      | 0.001*          |
| Female (%)                  | 250 (46.9)      | 145 (56.6)      | 89 (38.5)       | 16 (34.8)       |
| Male (%)                    | 283 (53.1)      | 111 (43.4)      | 142 (61.5)      | 30 (65.2)       |
| Comorbidity (Yes)           | 401 (75.2)      | 199 (77.8)      | 170 (73.6)      | 32 (69.6)       | 0.37            |
| APACHE II                   | 16.9 ± 7.4      | 16.3 ± 6.7      | 16.6 ± 7.7      | 21 ± 11.2       | 0.14            |
| SOFA                        | 4.3 ± 2.5       | 4.1 ± 2.2       | 4.2 ± 2.2       | 6.5 ± 3.9       | <0.001*         |
| **Laboratory values**       |                 |                 |                 |                 |                 |
| White blood cells (× 10^9/μL) | 11.4 ± 6.8     | 11.2 ± 7.7      | 11.4 ± 5.8      | 12 ± 6.1        | 0.14            |
| Neutrophil (× 10^9/μL)      | 9.5 ± 5.1       | 9.2 ± 5.5       | 9.6 ± 4.5       | 10.5 ± 5.4      | 0.047*          |
| Lymphocyte (× 10^9/μL)      | 1.4 ± 4.5       | 1.6 ± 6.0       | 1.2 ± 2.6       | 1.0 ± 0.77      | 0.43            |
| Platelet (× 10^9/μL)        | 247 ± 104       | 243 ± 101       | 246 ± 101       | 272 ± 137       | 0.61            |
| Prothrombin time (s)        | 140 ± 5.1       | 139 ± 5.1       | 137 ± 2.6       | 166 ± 11.0      | 0.08            |
| aPTT (s)                    | 31.4 ± 14.8     | 31.3 ± 19.3     | 31.1 ± 9.0      | 329.6 ± 6.6     | 0.025*          |
| D-dimer (ng/ml)             | 1942 ± 4776     | 2065 ± 5581     | 1657 ± 3512     | 2686 ± 5391     | 0.09            |
| C-reactive protein (mg/L)   | 139 ± 88        | 129 ± 87        | 150 ± 88        | 135 ± 82        | 0.031*          |
| Lactate dehydrogenase (U/L) | 524 ± 433       | 395 ± 171       | 535 ± 207       | 1188 ± 1135     | <0.001*         |
| Creatine kinase (U/L)       | 326 ± 803       | 147 ± 227       | 410 ± 595       | 896 ± 2230      | <0.001*         |
| Alanine aminotransferase (U/L) | 47 ± 112       | 16 ± 7          | 39 ± 20         | 256 ± 313       | <0.001*         |
| Aspartate aminotransferase (U/L) | 76 ± 247       | 26 ± 8          | 57 ± 22         | 457 ± 747       | <0.001*         |
| Total bilirubin (mg/dl)     | 0.73 ± 0.52     | 0.58 ± 0.25     | 0.8 ± 0.42      | 1.26 ± 1.23     | <0.001*         |
| Direct bilirubin (mg/dl)    | 0.42 ± 0.72     | 0.36 ± 0.92     | 0.4 ± 0.23      | 0.82 ± 0.9      | <0.001*         |
| Indirect bilirubin (mg/dl)  | 0.36 ± 0.67     | 0.27 ± 0.16     | 0.45 ± 0.99     | 0.43 ± 0.37     | <0.001*         |
| Procalcitonin (ng/ml)       | 3.8 ± 15.9      | 3.1 ± 16.7      | 3.3 ± 11.4      | 10.0 ± 26.5     | 0.001*          |
| Ferritin (μg/L)             | 874 ± 639       | 723 ± 579       | 985 ± 636       | 1160 ± 766      | <0.001*         |
| Intensive care unit days    | 11.3 ± 10.7     | 12.1 ± 11       | 10.6 ± 9.5      | 10.3 ± 13.9     | 0.033*          |

* Statistically significant; APACHE II=Acute Physiology and Chronic Health Evaluation II score; SOFA=Sequential Organ Failure Assessment score; aPTT=Activated partial thromboplastin time;

![Table 3](image)

**Table 3**

**Comparison of 7-day, 28-day and total mortality rates between groups.**

|                  | Total (n = 533) | Group 1 (n = 256) | Group 2 (n = 231) | Group 3 (n = 46) | p value |
|------------------|-----------------|-------------------|-------------------|-----------------|---------|
| 7-days mortality |                 |                   |                   |                 |         |
| Yes              | 167 (31.3)      | 66 (25.8)         | 77 (33.3)         | 24 (52.2)       | 0.001*  |
| No               | 366 (68.7)      | 190 (74.2)        | 154 (66.7)        | 22 (47.8)       |         |
| 28-days mortality|                 |                   |                   |                 |         |
| Yes              | 345 (64.7)      | 147 (57.4)        | 165 (71.4)        | 33 (71.7)       | 0.003*  |
| No               | 188 (35.3)      | 109 (42.6)        | 66 (28.6)         | 13 (28.3)       |         |
| Total mortality  |                 |                   |                   |                 | 0.004*  |
| Yes              | 353 (66.2)      | 152 (59.4)        | 165 (71.4)        | 36 (78.3)       |         |
| No               | 180 (33.8)      | 104 (40.6)        | 66 (28.6)         | 10 (21.7)       |         |

* Statistically significant
hospitalization in patients with liver damage in the critically patient group was numerically higher than in patients without liver damage, but this was not statistically significant [11]. In our study, it was found that the time of stay at the ICU in patients with liver biochemical parameters abnormality and liver injury were shorter than patients with normal liver biochemical parameters. We think that hospitalization periods in critically patients who had COVID-19 are affected by many factors, and the high mortality rates in the liver biochemical parameters abnormality and liver injury groups may cause a short stay in the ICU.

Many studies have reported that abnormal liver biochemical parameters, especially elevated AST and ALT, are associated with increased disease severity and mortality in COVID-19 patients [7,12,24,25,27,44]. Yip et al. stated that ALT / AST elevation and acute liver damage in patients with COVID-19 were independently associated with mortality and that such biochemical changes had important consequences [21]. Huang et al. stated that dynamic changes of ALT and AST levels in COVID-19 patients were more pronounced in patients with liver function damage and in patients who died. The patients with AST > three times the upper limit of normal (ULN) have the highest risk of death and mechanical ventilation [45]. Lei et al. reported that elevated ALT, AST, ALP, and total bilirubin levels in COVID-19 patients are associated with an increased risk of death and that elevated AST among these liver enzymes is associated with the highest risk of death [12]. In their study, Chen et al. noted that ALT, AST, GGT, ALP, and total bilirubin concentrations were significantly higher in patients who died than in healed patients; and that approximately 52% of patients who died and 16% of those who recovered had high AST levels [29]. Again Kulkarni et al., in their meta-analysis, found a higher rate of abnormal liver biochemical parameters results in the non-survive group at the first admission compared to the survive group in COVID-19 patients [39]. In our study, in line with previous studies, it was found that in patients with liver biochemical parameters abnormality and liver injury had higher total, 7-day, and 28-day mortality rates compared to patients with normal liver biochemical parameters.

This study has some limitations. Our data were not capable of evaluating the causality of liver damage and poor clinical outcomes associated with COVID-19.

5. Conclusions

As a result, liver dysfunction evaluated by biochemical blood analysis (AST, ALT, and total bilirubin levels) is common in critical COVID-19 patients followed in the ICU. Abnormal liver biochemical parameters are closely related to an increased risk of mortality in critically ill COVID-19 patients. Therefore, these indicators should be closely monitored during the stay in the ICU and special attention should be paid to liver damage.

Authors’ contributions

FS is the first author. Each author either made substantial contributions to the conception or design of the work. FS, CKK, and OU wrote the paper. Each author involved in the acquisition, analysis, or interpretation of data for the work. FS, MB and OU were involved in data cleaning, mortality follow-up, and verification. Each author drafted the manuscript or revised it critically for important intellectual content; and provided final approval of the version to be published. All authors have read and approved the final manuscript. FS and CKK are the study guarantors.

Clinical trials

The trial was registered with clinicaltrials.gov (NCT04669509).

Funding

No funding was used toward the development of this study and there are no financial interests or conflicts of interests related to this work.

Conflicts of interest

The authors declare that they have no conflict of interest.

Acknowledgements

We would like to thank Sedat Kaya for his invaluable help and support on this project.

References

[1] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA J Am Med Assoc 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1565.
[2] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.
[3] Zhou P, Yang X, Lou, Wang XG, Chen L, Shu C, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):470–3. https://doi.org/10.1038/s41586-020-2274-8.
[4] Chai X, Hu B, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv 2020. https://doi.org/10.1101/2020.03.09.973176.
[5] Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19 related liver functional abnormality. Clin Gastroenterol Hepatol 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002.
[6] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
[7] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73(3):566–74. https://doi.org/10.1016/j.jhep.2020.04.006.
[8] Feng G, Zheng KL, Yan QQ, Rios RS, Targher G, Byrne CD, et al. Covid-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8(1):18–24. https://doi.org/10.14218/JCH.2020.00018.
[9] Zhang Y, Zheng L, Liu L, Mao X, Zhao Q, Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int 2020;40(9):1095–103. https://doi.org/10.1111/liv.14455.
[10] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–2. https://doi.org/10.1016/S2213-2600(20)30076-X.
[11] Jiang S, Wang R, Li L, Hong D, Fu R, Rao Y, et al. Liver injury in critically ill and non-critically ill COVID-19 patients: a multicenter, retrospective, observational study. Front Med 2020;7:347. https://doi.org/10.3938/fmmed.2020.0347.
[12] Lei F, Liu YM, Zhou F, Qin J, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020;72(2):389–98. https://doi.org/10.1002/hep.31301.
[13] WHO Clinical management of COVID-19 [cited Oct 25 2020]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
[14] T.R. Ministry of Health COVID-19 information page. The management of Severe Pneumonia, ARDS, Sepsis and Septic Shock [cited Dec 30 2020 ]. doi: 10.18678/dtdfl.880733
[15] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges [Innere]. Lancet Gastroenterol Hepatol 2020;5(5):426–30. https://doi.org/10.1016/S2468-1253(20)30057-1.
[16] Medetaliyevyglu A, Catma Y, Senkal N, Ormeci A, Cavus B, Kose M, et al. The effect of liver test abnormalities on the prognosis of COVID-19. Ann Hepatol 2020;19(6):614–21. https://doi.org/10.1016/j.aohep.2020.08.058.
[17] Chen F, Chen W, Chen J, Xu D, Xie W, Wang X, et al. Clinical features and risk factors of COVID-19-associated liver injury and function: a retrospective analysis of 830 cases. Ann Hepatol 2021;21(1):100267. https://doi.org/10.1016/j.aohep.2020.09.011.
[18] Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormality and death with COVID-19 in 332 patients with COVID-19 in Shanghai, China. Aging 2020;12(19):18844. https://doi.org/10.18632/aging.103860.
[21] Yip TCF, Lui GCY, Wong VWS, Chow VCY, Ho THY, Li TCM, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut 2021;70(4):733–42. https://doi.org/10.1136/gutjnl-2020-321726.

[22] Chu H, Bai T, Chen L, Hu L, Xiao Y, Yao L, et al. Multicenter analysis of liver injury patterns and mortality in COVID-19. Front Med 2020;7. https://doi.org/10.3389/fmed.2020.584342.

[23] Xie H, Zhao J, Liu L, Liu S, Zhao C, Kong X, et al. Multicenter analysis of liver injury in COVID-19 patients with liver injury: a retrospective study. Liver Int 2020;40(6):1321–6. https://doi.org/10.1111/liv.14448.

[24] Zhou F, Yu T, Duan R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.

[25] Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. hospital network. Hepatology 2020;72(3):807–17. https://doi.org/10.1002/hep.31404.

[26] Weber S, Hellmuth JC, Scherer C, Muenchhoff M, Mayerle J, Gerbes AL. Liver function and clinical parameters in patients with COVID-19: a retrospective observational cohort study of 1827 patients in a major U.S. hospital network. Hepatology 2020;72(4):1169–76. https://doi.org/10.1002/hep.31487.

[27] Piano S, Dalbeni A, Vettore E, Benfaredo M, Mattioli M, Gambino CG, et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int 2020;40(10):2394–406. https://doi.org/10.1111/liv.14565.

[28] Roedl K, Jarczak D, Droz A, Wichmann D, Boenisch O, de Heer G, et al. Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect? Ann Intensive Care 2021;11(1):1–11. https://doi.org/10.1186/s13613-021-00835-3.

[29] Wang M, Yan W, Qi W, Wu D, Zhu L, Li W, et al. Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatol Int 2020;14(5):723–32. https://doi.org/10.1007/s12072-020-00751-5.

[30] Zhang SS, Dong L, Wang GM, Tian Y, Ye XF, Zhao Y, et al. Progressive liver injury and increased mortality risk in COVID-19 patients: a retrospective cohort study in China. World J Gastroenterol 2021;27(9):835–53. https://doi.org/10.3748/wjg.v27.i9.835.

[31] Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.

[32] Kulkarni AV, Kumar P, Teervhia HV, Premkumar M, Arab JP, Candra R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19 [Internet]. Alimentary Pharmacol Ther 2020;52(4):584–99. https://doi.org/10.1111/apt.15916.

[33] Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections [Internet]. Liver Int 2020;40(5):998–1004. https://doi.org/10.1111/liv.14435.

[34] Hundt MA, Deng Y, Ciarleglio MM, Nathansone MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1827 patients in a major U.S. hospital network. Hepatology 2020;72(4):1169–76. https://doi.org/10.1002/hep.31487.

[35] Parohan M, Yaghoubi S, Seraji A. Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies. Hepatol Res 2020;50(8):924–35. https://doi.org/10.1111/hepr.13510.

[36] Cao W, Shi L, Chen L, Xu X, Wu Z. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei [Internet]. medRxiv 2020. https://doi.org/10.1101/2020.02.23.20026963.

[37] Ye L, Chen B, Wang Y, Yang Y, Zeng J, Deng G, et al. Prognostic value of liver biochemical parameters for COVID-19 mortality. Ann Hepatol 2021;21:100279. https://doi.org/10.21143/ah.2020.10.007.

[38] Huang H, Chen S, Li H, Zhou XL, Dai Y, Wu J, et al. The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan. Aliment Pharmacol Ther 2020;52(6):1051–9. https://doi.org/10.1111/apt.15562.